Bio-Gene Technology Ltd Stock Price Today
Bio-Gene Technology Ltd stock price today. Bio-Gene Technology Ltd (AU:BGT) is currently trading at AU$0.01 AUD, up 0.00% today. Over the past 52 weeks, shares have ranged between AU$0.01 and AU$0.04. This page tracks Bio-Gene Technology Ltd's live share price on the AU exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see BGT cash generation efficiency.
Share Price of Bio-Gene Technology Ltd — Daily History & Trading Volume
Share price of Bio-Gene Technology Ltd over the past year. The chart below tracks Bio-Gene Technology Ltd's daily closing share price and trading volume on the AU exchange over the past year, giving a clear view of recent price momentum and liquidity.
Bio-Gene Technology Ltd Stock Trading Volume
Bio-Gene Technology Ltd stock trading volume shows how many shares changed hands each day on the AU exchange.
Bio-Gene Technology Ltd Income Statement — Revenue, Profit & Earnings by Year
Bio-Gene Technology Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | AU$425.07K | AU$18.32K | AU$149.23K | AU$445.73K | AU$62.61K |
| Cost of Revenue | AU$245.78K | AU$319.77K | AU$313.27K | AU$267.14K | AU$173.20K |
| Gross Profit | AU$-245.78K | AU$-301.45K | AU$-164.04K | AU$178.59K | AU$-110.59K |
| Research & Development | AU$1.38 Million | AU$1.07 Million | AU$1.98 Million | AU$1.90 Million | AU$1.68 Million |
| SG&A | AU$884.56K | AU$1.42 Million | AU$1.18 Million | AU$802.49K | AU$567.09K |
| Total Operating Expenses | AU$2.82 Million | AU$2.76 Million | AU$3.46 Million | AU$3.59 Million | AU$2.86 Million |
| Operating Income | AU$-3.07 Million | AU$-3.06 Million | AU$-3.63 Million | AU$-3.41 Million | AU$-2.60 Million |
| EBITDA | AU$-2.58 Million | AU$-2.97 Million | AU$-3.14 Million | AU$-2.92 Million | AU$-2.85 Million |
| EBIT | AU$-2.62 Million | AU$-3.01 Million | AU$-3.18 Million | AU$-2.97 Million | AU$-2.91 Million |
| Interest Expense | — | — | — | AU$52.86K | AU$337.00 |
| Income Before Tax | AU$-2.58 Million | AU$-3.01 Million | AU$-3.10 Million | AU$-2.91 Million | AU$-2.40 Million |
| Income Tax Expense | AU$-385.63K | AU$-604.19K | AU$-445.85K | AU$-434.05K | AU$-510.51K |
| Net Income | AU$-2.58 Million | AU$-2.41 Million | AU$-3.10 Million | AU$-2.91 Million | AU$-2.40 Million |
Bio-Gene Technology Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Bio-Gene Technology Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | AU$2.15 Million | AU$3.16 Million | AU$3.84 Million | AU$7.30 Million | AU$5.00 Million |
| Total Current Assets | AU$1.97 Million | AU$2.94 Million | AU$3.58 Million | AU$7.00 Million | AU$4.66 Million |
| Cash & Equivalents | — | — | — | — | AU$3.93 Million |
| Short-term Investments | AU$500.00K | AU$1.50 Million | — | AU$74.20K | — |
| Net Receivables | AU$472.42K | AU$523.96K | AU$445.55K | AU$438.17K | AU$523.75K |
| Inventory | — | — | AU$70.19K | AU$148.84K | AU$132.87K |
| Property, Plant & Equipment | AU$13.35K | AU$19.01K | AU$14.64K | AU$22.99K | AU$22.73K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | AU$522.98K | AU$368.45K | AU$613.88K | AU$1.03 Million | AU$754.57K |
| Total Current Liabilities | AU$510.13K | AU$345.93K | AU$573.87K | AU$1.01 Million | AU$592.71K |
| Long-term Debt | — | — | AU$0.00 | AU$0.00 | AU$150.00K |
| Net Debt | AU$-1.14 Million | AU$-2.21 Million | AU$-2.99 Million | AU$-6.34 Million | AU$-3.93 Million |
| Total Stockholder Equity | AU$1.63 Million | AU$2.79 Million | AU$3.22 Million | AU$6.27 Million | AU$4.25 Million |
| Retained Earnings | AU$-22.03 Million | AU$-19.64 Million | AU$-17.43 Million | AU$-14.50 Million | AU$-11.68 Million |
Bio-Gene Technology Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Bio-Gene Technology Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | AU$-2.54 Million | AU$-2.75 Million | AU$-3.28 Million | AU$43.52K | AU$-1.83 Million |
| Capital Expenditures | AU$0.00 | AU$5.70K | AU$0.00 | AU$6.84K | AU$3.03K |
| Free Cash Flow | AU$-2.54 Million | AU$-2.76 Million | AU$-3.28 Million | AU$36.67K | AU$-1.83 Million |
| Investing Cash Flow | AU$0.00 | AU$-5.70K | AU$0.00 | AU$-6.84K | AU$-3.03K |
| Financing Cash Flow | AU$1.47 Million | AU$1.98 Million | AU$-75.00K | AU$4.41 Million | AU$239.88K |
| Dividends Paid | — | — | — | AU$75.00K | AU$11.66K |
| Stock-Based Compensation | — | — | AU$48.66K | AU$453.01K | AU$367.53K |
| Depreciation | AU$41.93K | AU$38.38K | AU$45.30K | AU$43.52K | AU$54.22K |
| Change in Cash | AU$-1.07 Million | AU$-780.97K | AU$-3.35 Million | AU$2.41 Million | AU$-1.59 Million |
Bio-Gene Technology Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Bio-Gene Technology Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 25, 2026 | — | — | — |
| Aug 25, 2025 | -0.01 | 0.00 | — |
| Feb 27, 2025 | -0.01 | 0.00 | — |
| Oct 31, 2024 | — | — | — |
| Feb 23, 2023 | -0.01 | — | — |
| Aug 15, 2022 | -0.01 | — | — |
| Feb 16, 2022 | -0.01 | 0.00 | — |
| Aug 26, 2021 | -0.01 | — | — |